There is a need for more effective and more easily accessible therapy options for patients with relapsed or refractory multiple myeloma (RRMM). Teclistamab is a bispecific antibody that showed deep and durable responses in heavily pretreated patients with RRMM in the phase 1/2 MajesTEC-1 trial. The aim of this trial (MajesTEC-3) was to evaluate the efficacy and safety of teclistamab combined with daratumumab (which has synergistic effects with teclistamab) versus investigator’s choice of a daratumumab-based regimen in patients with RRMM.

Venetoclax is a highly selective BCL-2 inhibitor that has shown promising efficacy and tolerability in patients with relapsed or refractory multiple myeloma (RRMM) with t(11;14)- positive cells, particularly in combination with dexamethasone, which enhances BCL-2 dependency. The aim of this study was to investigate the efficacy and safety of venetoclax plus dexamethasone compared with pomalidomide plus dexamethasone in patients with t(11;14)-positive RRMM.

In patients with multiple myeloma, venous thromboembolism (VTE) is a frequent and life-threatening complication that can decrease life expectancy, interfere with scheduled treatment and negatively impact a patient’s quality of life. Effective prevention and management of VTE in this population would improve patient outcomes. On behalf of the European Myeloma Network, the aim of this article was to provide evidence-based recommendations for VTE prevention and treatment in patients with multiple myeloma.

The treatment of multiple myeloma using high-dose chemotherapy and autologous stem-cell transplantation (HDT/ASCT) as induction therapy is a standard approach in patients younger than 65 years, but its feasibility and efficacy in older patients is less certain. The aim of this study was to compare outcomes following HDT/ASCT treatment in patients with multiple myeloma aged ≤65 versus >65 years.